ctDNA Utilization in Early-Stage NSCLC

Liquid biopsy using circulating tumor DNA (ctDNA) is emerging as a valuable tool in early-stage NSCLC, with the potential to complement or, in some cases, substitute for tissue-based testing. ctDNA analysis offers a minimally invasive approach to detect actionable mutations, monitor minimal residual disease, and identify recurrence earlier than imaging alone. Reflex testing—automatically initiating biomarker analysis on available tissue or plasma at diagnosis—can streamline workflows, reduce delays in treatment planning, and ensure that molecular results are available to guide adjuvant therapy decisions. Integrating ctDNA into reflex testing protocols may enhance early detection and personalized treatment strategies in early-stage NSCLC.